Vendor Intelligence Report: Swiss Chems

Published 13 Jun 2026. 27-page investigative report on who is behind Swiss Chems: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 10 Finnrick lab tests, Swiss Chems passes 4 and fails 6, for a 40% overall pass rate. The tested catalog is not uniformly bad, but it is not stable: Ipamorelin and BPC-157 are the less-bad signals, with some passing lots, while CJC-1295 is the clear avoid. One CJC-1295 certificate in the file reported 1.69% purity, and the product does not recover into a dependable vendor-product signal. Ratings also shrink under stricter grading, which makes the mixed passes less reassuring.

The non-lab record raises a separate accountability problem. Swiss Chems can support a 2018-era brand origin through domain and Wayback evidence, but the current public surface does not identify a legal entity, owner, lab director, or operating company. The listed New York address sits in virtual-office context, exact-name U.S. registry searches came back empty, and the current Iceland-domain record shows a Belize registrant country plus Cloudflare masking. The FDA’s December 2024 warning letter adds a harder external marker: regulators cited Semaglutide and Retatrutide sales and rejected the practical value of the research-use-only posture.

Quality documentation does not close the gap. Swiss Chems’ own “Independent Test Results” gallery includes COA material that does not name an independent lab, does not provide independently verifiable lot linkage in the reviewed sample, routes verification back to the vendor site, and includes a Trevogrumab signature reading al. Chems. The report also carries a confidence-medium operator lead to Charles Anthony Hughes / Dr. Tony Huge and the Enhanced Athlete pattern, plus a referral-code ecosystem where undisclosed promotion can make source recommendations look more independent than they are.

Inside the full report:

  • Appendix A laboratory data, per-product pass/fail history, rating trajectories, and methodology-divergence charts for all 3 Finnrick-tested products.
  • FDA Warning Letter MARCS-CMS 695663 analysis, including the cited GLP-1 products and the research-use-only issue.
  • Domain timeline covering swisschems.com, swisschems.is, swisschems.co, WHOIS records, Cloudflare masking, and Wayback captures.
  • Corporate trace checks across Delaware, Wyoming, OpenCorporates, LinkedIn, PACER, Panjiva, and ImportYeti, including negative results.
  • COA authentication review of the Independent Test Results page and Trevogrumab certificate artifacts.
  • Affiliate and reputation scan covering referral codes, coupon pages, Trustpilot complaint themes, payment-currency anomalies, and unverified substitution leads.

Risk assessment

  • Product-quality risk — CJC-1295 — high: Finnrick CJC-1295 record is 3 tests with 0 pass / 3 fail and a 20.73% current rating; individual certificates cited 1.69% and 54.44% purity.
  • Product-quality risk — Ipamorelin — medium: Finnrick Ipamorelin record is mixed at 4 tests with 2 pass / 2 fail and a 64.96% current rating; passing lots exist but reliability is not clean.
  • Product-quality risk — BPC-157 — medium: Finnrick BPC-157 record is 3 tests with 2 pass / 1 fail and a 50.66% current rating; acceptable samples exist but the product remains method-sensitive and mixed.
  • Unverifiable COA risk — high: Swiss Chems COAs do not name the lab, lack verifiable batch/lot data, route QR checks back to vendor pages, and one Trevogrumab signature reads al. Chems.
  • FDA enforcement / catalog-continuity risk — high: FDA Warning Letter MARCS-CMS 695663, dated Dec. 10, 2024, cited Semaglutide and Retatrutide and rejected the research-use-only defense, creating enforcement and catalog-continuity risk.
  • Corporate-accountability risk — high: No exact-name Swiss Chems/SwissChems entity surfaced in Delaware, Wyoming, or OpenCorporates; site uses virtual NY address and Belize .is registrant.
  • Possible operator-history risk — medium: Forum evidence and operational overlaps suggest possible Charles Anthony Hughes / Dr. Tony Huge linkage; no corporate record confirms control, but Enhanced Athlete history raises accountability concerns.
  • Affiliate-promotion risk — medium: Official program offers 20% commissions; scan found 26 code/referral promoters, with 23 lacking clear disclosure and 1 unclear.
  • Domain-verification / brand-confusion risk — medium: Active .is, historical .com, unverified .co, and a Trustpilot .io profile coexist without an authoritative channel/reseller list or independent verification portal.
  • Fulfillment and payment-dispute risk — medium: Trustpilot profile shows 2.2/5 across 14 reviews with 86% 1-star; complaints include expired products, delays, customs seizures, and peso-denominated card billing.